DOJ Pressure Mounts: Pill Network Exposed?

Medicine pills and syringe on table with brown bottle — Photo: Adul10 / Shutterstock

At the center of the latest fight over medication abortion is not a clinic or a courtroom, but an online logistics hub that a sitting senator now wants the Justice Department to treat as a criminal enterprise.

Key Points

Sen. Josh Hawley has filed a formal criminal referral urging the DOJ to investigate Plan C, an abortion-pill access project he labels a “left-wing dark money operation” and a referral hub for pills mailed into states that restrict them.
Hawley’s letter alleges that Plan C connects women to manufacturers, foreign clinics, and online vendors shipping mifepristone into states like Florida, Oklahoma, and Texas where mailing abortion drugs is prohibited by state law.
He argues the network may violate federal prescription-drug rules, laws against importing unapproved drugs, and conspiracy or aiding-and-abetting statutes, and asks DOJ to scrutinize potential ties to manufacturers Danco Laboratories and GenBioPro.
The referral is part of a broader national struggle over whether mail-order and telehealth abortion services are lawful healthcare or illegal interstate distribution, a dispute that has played out in Comstock Act arguments, FDA litigation, and multiple state enforcement actions.
To date, there is no public indication that DOJ has opened a case against Plan C; the referral marks an escalation in political and legal pressure, not a finding of criminal liability.

Hawley’s Criminal Referral: What He Is Asking DOJ To Do

Senator Josh Hawley’s move is unusually direct: he has transmitted a formal criminal referral to Acting Attorney General Todd Blanche urging the Department of Justice to “investigate and prosecute” Plan C. In Hawley’s telling, Plan C is not a neutral information site but “a left-wing dark-money operation” that has organized the mailing of the abortion drug mifepristone into states where such shipments are forbidden under state law. His Senate office describes new information about “an organized international effort to profit from the violation of state and federal law,” with Plan C allegedly at the center.

In the referral, Hawley asks DOJ to open a criminal investigation into three specific areas: Plan C itself; its relationships with what he calls “potential co-conspirator manufacturers” of mifepristone; and the wider network of suppliers—domestic and foreign—whom Plan C reportedly promotes to users. This is not presented as a general policy critique of medication abortion; the document is framed as a request for case-building around identifiable actors, supply routes, and legal theories.

Plan C as “Referral and Logistics Hub” for Mailed Abortion Pills

Hawley’s accusations hinge on how Plan C operates in practice. In public remarks and in the referral, he alleges that Plan C styles itself as a “public health information campaign” but functions instead as “the referral and logistics hub for shipping abortion drugs into states whose laws prohibit it.” Fox News, which obtained and reported on the letter, echoes that description, calling Plan C an online marketplace that facilitates mailing abortion chemicals to “points in states where they are banned.”

According to Hawley, the site directs women in states such as Florida, Oklahoma, and Texas—jurisdictions that explicitly bar providers from mailing abortion drugs—to obtain pills by mail from a mix of sources. That includes two foreign clinics that, he alleges, ship mifepristone to U.S. addresses from abroad, as well as online vendors that sell abortion drugs without requiring prescriptions, identification, or medical consultation. Plan C’s own materials acknowledge that some of these pills are not regulated or inspected by the U.S. government, which Hawley cites as part of the risk architecture he wants DOJ to examine.

Hawley also points to Plan C’s guidance on digital privacy. The referral describes the project advising users to employ privacy-focused web browsers, VPNs, and encrypted email services, ostensibly to minimize detectability when seeking pills online. Plan C’s content, as summarized in the referral and reporting, warns users about potential legal consequences but leaves decisions about risk to individuals, a posture Hawley interprets as facilitation rather than neutrality.

Manufacturers, Foreign Clinics, and the Alleged Network Structure

Beyond Plan C itself, Hawley wants DOJ to reconstruct the network he claims ties the site to manufacturers and distant suppliers. One focal point is Danco Laboratories, the original manufacturer of mifepristone. Hawley notes that Danco lists Plan C among patient resources on its website, which he argues effectively steers prospective customers to an organization that “instructs Americans on how to break the law.” He suggests that GenBioPro, the generic manufacturer of mifepristone, maintains a similar referral relationship and urges DOJ to determine “the full extent of these relationships, including any financial ties.”

This referral builds on Hawley’s separate push for a probe into Danco itself. In earlier correspondence, he asked DOJ to investigate Danco’s FDA approval, regulatory compliance, manufacturing and distribution pipeline, and safety disclosures, citing data that place serious adverse events following mifepristone abortion around 10.9% and referencing FDA reports of deaths associated with the drug since 2000. In the Plan C referral, the emphasis shifts from drug risks to alleged coordination: the idea that manufacturers and Plan C, acting together, help women circumvent state-level bans or restrictions by routing pills through mail and foreign suppliers.

For the foreign clinics and vendors that Plan C reportedly lists, Hawley does not publish shipment records, tracking data, or customs documents in his release. He instead describes, in general terms, clinics abroad mailing mifepristone into the United States and online merchants providing unregulated pills, and asks DOJ to use its tools—subpoenas, customs access, regulatory oversight—to determine how those flows intersect with Plan C’s referral traffic.

The Legal Theories: State Bans, Federal Drug Law, and Conspiracy

Hawley’s referral sketches several overlapping legal theories. First, he grounds his argument in state statutes that either ban medication abortion outright or specifically prohibit mailing abortion drugs to patients. His office highlights that Florida, Oklahoma, and Texas fall into the latter category, barring providers from sending mifepristone through the mail even if the drug itself is legal under federal approval. Plan C’s guidance for residents of those states—showing them how to obtain pills by mail anyway—is framed as direct facilitation of state-law violations.

Second, Hawley points to federal prescription-drug rules and importation law. He asserts that selling abortion pills without prescriptions or medical oversight may violate provisions of the Food, Drug, and Cosmetic Act governing the dispensing of prescription-only medications. He further alleges possible violations of laws that bar importing unapproved drugs into interstate commerce, particularly where foreign clinics ship pills that are not sourced through FDA-regulated channels.

Finally, he invokes federal conspiracy and aiding-and-abetting concepts. The referral asks DOJ to assess whether Plan C, manufacturers, and remote suppliers are engaged in a coordinated effort that could satisfy the elements of conspiracy—agreement, overt acts, and unlawful objective—or aiding and abetting of state-law offenses. One detail he highlights is Plan C’s referrals to providers willing to prescribe abortion pills up to 14 weeks of pregnancy, exceeding the FDA-approved labeling for mifepristone and surpassing limits in several states. That, he argues, may bring both prescribers and referrers within reach of federal enforcement.

How Mail-Order Abortion Became a Legal Battleground

Hawley’s referral does not arise in a vacuum; it plugs directly into a broader, ongoing struggle over medication abortion by mail. Since the Dobbs decision upended federal constitutional protection for abortion, conservative lawmakers and advocacy groups have repeatedly argued that mailing mifepristone is illegal under the Comstock Act, a set of nineteenth-century laws that ban the shipment of “obscene” materials and items used to provide unlawful abortion care. Those actors have petitioned DOJ, state attorneys general, and federal courts to treat the mailing and online prescribing of abortion pills as prohibited distribution rather than ordinary healthcare.

On the other side, DOJ’s Office of Legal Counsel issued an opinion concluding that the Postal Service may deliver prescribed abortion medication, even into states with severe abortion restrictions, so long as the sender lacks specific intent that the drugs be used unlawfully. That opinion, and subsequent Supreme Court decisions allowing telemedicine prescriptions and mail delivery of mifepristone to resume after lower-court interruptions, have underpinned a national expansion of remote abortion care and reinforced the view, among abortion-rights advocates, that federal authorization and preemption protect such practices.

The result is a patchwork. As of mid-2026, mifepristone is banned or nearly banned in 13 states, and 28 states impose some form of restriction on medication abortion. Six states explicitly prohibit telehealth for medication abortion, while others require in-person visits or bar providers from mailing pills. Meanwhile, providers and projects like Plan C emphasize ways to obtain pills online from out-of-state or overseas sources, arguing that hundreds of thousands of people have used mailed pills without legal trouble, though they acknowledge a small fraction of cases where individuals have faced criminal charges.

“Dark Money” and the Politics Around Plan C

Hawley’s language around Plan C is sharply political. He repeatedly calls it a “left-wing dark money operation,” a phrase designed to evoke anonymous donors, opaque flows of funds, and ideological activism. That rhetoric aligns with his broader campaign against what he describes as Soros-linked and other left-leaning nonprofit networks, which he has criticized in hearings dealing with protest funding and progressive causes.

At this stage, however, the public materials tied to the Plan C referral do not include financial records, IRS filings, or donor lists that substantiate the “dark money” label as a technical description. The Texas Attorney General’s office, in a separate cease-and-desist letter, alleged that Plan C, as a project of Possibility Labs, facilitates shipment of abortion drugs into Texas in violation of state and federal law, but likewise focused on conduct, not funding sources. Hawley’s emphasis on “dark money” therefore reflects a political frame on top of his legal claims, rather than an independently documented audit of the project’s finances.

For Plan C and its allies, the risk is reputational as much as legal. In a polarized environment, calling an entity “dark money” can shape public perception long before any enforcement agency has tested the underlying facts. Supporters face a dual challenge: defending the legality of mail-order abortion logistics and countering the suggestion that their work is powered by undisclosed partisan funding streams.

‘Dark-Money’ Abortion Drug Dealer Hub Referred To Trump DOJ For Criminal Investigation

Websites like Plan C enable anyone with Internet access to order abortion pills to their door in less than a minute.

If your 12 year old daughter wants to order them- no problem!

Even if… pic.twitter.com/VnctutaSTO

— NWRain-Judi (@RYboating) July 21, 2026

What We Know, What We Don’t, and What Comes Next

It is important to distinguish between what Hawley’s referral establishes and what it does not. The existence of a criminal referral shows that a U.S. senator believes Plan C’s activities warrant investigation and has laid out a set of allegations and legal theories for DOJ to consider. It does not, on its own, prove that Plan C or any manufacturer, clinic, or vendor has violated federal law. There is no public indication that DOJ has opened an investigation, convened a grand jury, or filed charges arising from Hawley’s request.

The referral leans heavily on Plan C’s public-facing materials: lists of vendors, guidance on obtaining pills in restricted states, privacy advice, and links between the project and manufacturers’ resource pages. It does not publish underlying transactional data—shipment logs, payment records, import declarations—or internal communications that would provide granular evidence of coordination, intent, or profit-sharing. Those would be the sorts of documents DOJ would seek if it chose to act on the referral.

Meanwhile, litigation and enforcement around medication abortion continue on multiple fronts. Republican attorneys general have pursued suits challenging FDA’s regulatory decisions on mifepristone, and at least one physician has been indicted for mailing abortion medications into a ban state, raising fears among telemedicine providers. States like Texas have targeted organizations they say are increasing abortion-pill access in defiance of bans. On the other side, federal courts and agency opinions have, at least temporarily, sustained the legality of mail delivery under certain conditions.

Hawley’s Plan C referral slots into this landscape as an aggressive test case: can a referral-and-information project, one step removed from the physical pills, be treated as a criminal logistics hub? The answer will depend not only on statutory interpretation—especially of the Comstock Act and the Food, Drug, and Cosmetic Act—but on how investigators trace digital referrals to physical shipments and evaluate intent along the way. Until DOJ speaks, the referral remains both a political signal and a legal invitation rather than a resolved question.